Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Acadia Realty Trust | AKR | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 17.30 | 03:09:53 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.30 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 13.15 - 17.90 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 17.30 | USD |
Acadia Realty Trust Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.77B | 102.58M | - | 338.69M | 19.87M | 0.19 | 89.31 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Acadia Realty News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKR Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 16.53 | 17.555 | 16.51 | 17.16 | 957,335 | 0.77 | 4.66% |
| 1 Month | 16.92 | 17.61 | 16.135 | 16.93 | 724,008 | 0.38 | 2.25% |
| 3 Months | 16.51 | 17.90 | 16.095 | 16.86 | 975,396 | 0.79 | 4.78% |
| 6 Months | 15.96 | 17.90 | 15.475 | 16.87 | 1,044,852 | 1.34 | 8.40% |
| 1 Year | 13.25 | 17.90 | 13.15 | 15.97 | 918,324 | 4.05 | 30.57% |
| 3 Years | 21.79 | 23.33 | 12.28 | 17.00 | 735,890 | -4.49 | -20.61% |
| 5 Years | 28.16 | 29.5496 | 9.10 | 17.31 | 718,973 | -10.86 | -38.57% |
Acadia Realty Description
| Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |
